COLORADO SPRINGS, Colo., April 5 /PRNewswire/ -- "Because of the increased threat of corneal fungal infection, the body's natural defense mechanisms must be operating fully," says Terrence O'Brien, MD.
Dr. O'Brien is an esteemed corneal specialist and the Charlotte Breyer Rogers Distinguished Chair of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine.
Results from the CDC suggest a disturbing increase in fungal infection of the cornea that can lead to blindness.
Dr. O'Brien notes, "In addition to lysozyme and immunoglobulins, an adequate level of lactoferrin, the iron-binding protein in tears, is vital for the prevention of corneal infections."
The nutraceutical tear film support formulation, BioTears Oral GelCaps(R), has been suggested to increase tear lactoferrin levels with the Touch Scientific Lactoferrin Assay. Lactoferrin is an iron-binding protein and provides natural immune support.
The replication and biofilm formation of fungi, bacteria and viruses in mucosal tissues, including tears and saliva, are iron dependent. Growth of these pathogens becomes almost impossible if adequate amounts of iron-binding proteins, particularly lactoferrin, are concentrated in these fluids.
BioTears is a second-generation tear film formulation invented by Biosyntrx co-founders, Spencer Thornton, MD, Nashville, TN and Ellen Troyer, MT MA, Colorado Springs, CO.
The Biosyntrx Advisory Board includes well-known leaders in ophthalmic science including Howard Fine, MD, Eugene, OR; Jerre Freeman, MD, Memphis, TN; Richard Lindstrom, MD, Minneapolis, MN; Marguerite B. McDonald, MD, New Orleans, LA; Robert H. Osher, MD, Cincinnati, OH; Paul Sternberg, MD, Nashville, TN: Stephen Slade, MD, Houston, TX; Roger Steinert, MD, Irvine, CA; Stephen Whiting, PhD, San Diego, CA; and Betty Kamen, PhD, San Francisco, CA.
Biosyntrx is based in Lexington, SC, with research offices in Colorado Springs, CO. Its primary products include BioTears Oral GelCaps(R) and two full-spectrum multiples, Macula Complete(R) and Oculair(R). Biosyntrx is committed to proving the science that supports each formulation. For further information, visit www.biosyntrx.com or contact the third Biosyntrx co-founder and chief operating officer, Joe Kirkland, at 800-688-6815
BiosyntrxCONTACT: Ellen Troyer, MT MA of Biosyntrx, +1-719-227-7888
Web site: http://www.biosyntrx.com/
